Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News
August 16th 2023

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

July 31st 2023

ASCO 2023: Solid Tumors

June 20th 2023

FDA Sets Priority Review for Fruquintinib as ASCO Data Confirm Safety Results

April 17th 2023

Conversations on Equity in Cancer Care: Meet the Leaders of NCCN’s DEI Directors Forum

February 23rd 2023

David Jackman, MD, on Clinical Pathway Buy-in, Process for Updates

Video Interviews
View All
February 25th 2022

AstraZeneca's Camille Hertzka Discusses Interim PROpel Trial Findings in mCRPC

November 20th 2021

Dr Funmi Olopade: Breast Cancer Screening Is Not One Size Fits All

October 23rd 2021

Dr Funmi Olopade on WISDOM During COVID-19: Reaching Participants We Thought We Couldn’t Reach

July 17th 2021

Dr Christopher Arendt on Indication of TKIs in Solid Tumor and Blood Cancers

July 7th 2021

Dr Christopher Arendt on Positive Mobocertinib Results Seen in Metastatic NSCLC

June 23rd 2021

Dr Christopher Arendt Explains Mutually Exclusive Nature of EGFR Exon 20 Mutations in Metastatic NSCLC

June 16th 2021

Camille Hertzka on Real-World Implications of Durvalumab, Increasing Diversity in Clinical Trials

June 6th 2021

Dr Antoine Italiano on Extended Follow-up Findings of Larotrectinib in Patients With TRK Fusion Cancer

December 27th 2020

Dr Michael Korn Highlights a Key Takeaway From the Precision Medicine Session at QCCA’s Fall Meeting

December 13th 2020

Dr Michael Korn Outlines the Collaborative Nature of the Caris Precision Oncology Alliance

Podcasts
View All
January 24th 2020

Biomarker Testing in Advanced Colon Cancer: Why It's Still Lagging

August 25th 2019

Podcast: This Week in Managed Care—BRCA Testing Recommendation and Other Health News

August 1st 2018

Advancing Precision Oncology With the Syapse Precision Medicine Council

June 27th 2018

Exploring the Current State of Precision Medicine at the ASCO Annual Meeting

More News

May 2024 News From Strategic Alliance Partners
May 20th 2024

May 2024 News From Strategic Alliance Partners

AJMC Staff
Florida Cancer Specialists & Research Institute launches a new precision medicine venture; Tennessee Oncology announces promotions.
ACC 2023 Coverage: Topics in Cardio-oncology
April 18th 2023

ACC 2023 Coverage: Topics in Cardio-oncology

Mary Caffrey
Coverage from the American College of Cardiology Scientific Session Together With World Congress of Cardiology, held March 4-6, 2023, in New Orleans, Louisiana.
Ted Arrowsmith, MD
February 23rd 2023

OneOncology’s Clinical Pathways Covers Best Practices for 90% of Patients, Says Ted Arrowsmith, MD, MPH

Hayden E. Klein Laura Joszt, MA
State Legislatures Lead the Way on Policy Reform to Protect Personalized Medicine
February 22nd 2023

State Legislatures Lead the Way on Policy Reform to Protect Personalized Medicine

Angela Storseth-Cooper Lalan Wilfong, MD
Building More Diverse Clinical Trials in Oncology: Strategies for Providers, Payers, and Community Stakeholders
February 21st 2023

Building More Diverse Clinical Trials in Oncology: Strategies for Providers, Payers, and Community Stakeholders

Matthew Gavidia
Joseph Alvarnas, MD
February 21st 2023

Spotlights From Our Cochairs: Joseph Alvarnas, MD, Explains Barriers to Clinical Trial Diversity and Payer Participation

Hayden E. Klein
COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
June 23rd 2022

COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”

Mary Caffrey
Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.
FDA Accepts Futibatinib for Priority Review for FGFR2 Rearrangements and Fusions in Cholangiocarcinoma
March 30th 2022

FDA Accepts Futibatinib for Priority Review for FGFR2 Rearrangements and Fusions in Cholangiocarcinoma

AJMC Staff
Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.
Image of DNA in a test tube
February 23rd 2022

Further Analysis Needed to Incorporate Liquid Biopsy in the Community Setting

Maggie L. Shaw
This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.
Image of clinical research
February 18th 2022

Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study

Maggie L. Shaw
A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.
Image of lab research
February 15th 2022

Improvement Needed for Liquid Biopsy to Have Clinical Utility in Lung Cancer

Maggie L. Shaw
This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.
Image of precision medicine research
February 12th 2022

More Info Needed to Establish Utility of MRD, SFLC Levels as Biomarkers in MM

Maggie L. Shaw
This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.
Image of DNA sequencing
February 8th 2022

ctDNA Detection in RCC Requires More Sensitive Detection Methods

Maggie L. Shaw
Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.
Image of a blood sample for liquid biopsy
February 5th 2022

Liquid Biopsy May Have Prognostic, Theranostic Benefits in PDAC

Maggie L. Shaw
Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.
Image of a slide under a microscope
February 2nd 2022

Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer

Maggie L. Shaw
Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
dna image
January 27th 2022

Point-of-Care Testing Has Potential to Expand the Reach of NGS for CRC

Maggie L. Shaw
This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).
Image of DNA sequencing
January 24th 2022

MRD Continues to Reliably Predict Disease Progression in CRC

Maggie L. Shaw
In this poster presented at the 2022 ASCO Gastrointestinal Cancers Symposium, minimal residual disease (MRD) status as detected by postsurgery plasma cell-free DNA continued its strong track record of being a reliable predictor of disease progression in colorectal cancer (CRC).
Understanding Real-World Trends in MRD Testing as Part of MM Management
January 18th 2022

Understanding Real-World Trends in MRD Testing as Part of MM Management

Rose McNulty
An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.
Image of a blood drop made of red blood cells
January 16th 2022

MRD Kinetics Identify High-risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab

Rose McNulty
An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.
Image of scientist focusing on genetic medicine
January 13th 2022

Review Explores Adoption of New MRD Monitoring Method

Maggie L. Shaw
A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.
image of the brain
January 10th 2022

Targeted Cancer Therapies Showing Promise in Treating Parenchymal Brain Metastases

Jaime Rosenberg
Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.
lab researchers
January 7th 2022

MRD Indicates Relapse for Patients With Classical HL After ASCT

AJMC Staff
Minimal residual disease (MRD) can predict which patients with classical Hodgkin lymphoma (HL) will relapse after autologous stem cell transplantation (ASCT).
Lab researcher
December 26th 2021

Ibrutinib/Venetoclax Bests Chlorambucil/Obinutuzumab for Treating CLL

Maggie L. Shaw
Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.
Top 5 Most-Read Articles in Precision Oncology for 2021
December 25th 2021

Top 5 Most-Read Articles in Precision Oncology for 2021

Laura Joszt, MA
Epigenetics has a role in choosing the right medicine in lung cancer, artificial intelligence can predict outcomes in a highly aggressive cancer, and more.
Precision Medicine Can Close Oncology Gaps—and Lead to “Doing Less”
December 20th 2021

Precision Medicine Can Close Oncology Gaps—and Lead to “Doing Less”

Mary Caffrey
Physicians said it is in payers’ interest to use artificial intelligence to address social determinants of health, to cover tests, and to gather data. Doing so could let them stratify who needs certain screenings and diagnostic procedures and who doesn’t, which could lead to less consumption of health care.
Enhanced blood cell graphic
December 17th 2021

Daratumumab-Led Quad Therapy Aids MRD Surveillance in MM

Maggie L. Shaw
Final results from the MASTER trial presented at this year’s 63rd Annual American Society of Hematology Annual Meeting and Exposition bear out the benefits of quadruplet therapy and using minimal residual disease (MRD) status among patients with newly diagnosed multiple myeloma (MM).
Spotlighting Key Therapies in the Oncology Pipeline for the First Half of 2022
December 16th 2021

Spotlighting Key Therapies in the Oncology Pipeline for the First Half of 2022

Matthew Gavidia
Doc on computer accessing EMR
December 14th 2021

From Challenges Spring Opportunities for Progress in Daratumumab-Based Clinical Pathways

Maggie L. Shaw
An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.
Metastatic tumor
December 11th 2021

Real-world Study Shows Heterogenous Genomic Landscape of Metastatic LUAD

Jaime Rosenberg
The study demonstrated the heterogeneity of actionable alterations, PD-L1 expression, and mutational burden among the samples of metastatic lung adenocarcinomas (LUAD).
Tracing the Origins of Minimal Residual Disease
December 5th 2021

Tracing the Origins of Minimal Residual Disease

Allison Inserro
Although advancements in cancer have been many, disease relapse is still a hurdle for many types of tumors and malignancies, and there is an urgent need to overcome tumor resistance.
12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo